دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia
Patrick A. Brown, MD1; Lingyun Ji, PhD2; Xinxin Xu, MS3; Meenakshi Devidas, PhD4; Laura E. Hogan, MD5; Michael J. Borowitz, MD, PhD6; Elizabeth A. Raetz, MD7; Gerhard Zugmaier, MD8; Elad Sharon, MD, MPH9; Melanie B. Bernhardt, PharmD10; Stephanie A. Terezakis, MD11; Lia Gore, MD12; James A. Whitlock, MD13; Michael A. Pulsipher, MD14; Stephen P. Hunger, MD15; Mignon L. Loh, MD16
doi : 10.1001/jama.2021.0669
JAMA. 2021;325(9):833-842
Importance Standard chemotherapy for first relapse of B-cell acute lymphoblastic leukemia (B-ALL) in children, adolescents, and young adults is associated with high rates of severe toxicities, subsequent relapse, and death, especially for patients with early relapse (high risk) or late relapse with residual disease after reinduction chemotherapy (intermediate risk). Blinatumomab, a bispecific CD3 to CD19 T cell–engaging antibody construct, is efficacious in relapsed/refractory B-ALL and has a favorable toxicity profile.
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia
Franco Locatelli, MD, PhD1; Gerhard Zugmaier, MD2; Carmelo Rizzari, MD3; Joan D. Morris, MD4; Bernd Gruhn, MD5; Thomas Klingebiel, MD6; Rosanna Parasole, MD7; Christin Linderkamp, MD8; Christian Flotho, MD9; Arnaud Petit, MD, PhD10; Concetta Micalizzi, MD11; Noemi Mergen, MD2; Abeera Mohammad, MSc12; William N. Kormany, MD4; Cornelia Eckert, PhD13; Anja M?ricke, MD14; Mary Sartor, PhD15; Ondrej Hrusak, MD, PhD16; Christina Peters, MD17; Vaskar Saha, MD, PhD18,19; Luciana Vinti, MD, PhD1; Arend von Stackelberg, MD13
doi : 10.1001/jama.2021.0987
JAMA. 2021;325(9):843-854
Importance Blinatumomab is a CD3/CD19-directed bispecific T-cell engager molecule with efficacy in children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
Association of Intravenous Immunoglobulins Plus Methylprednisolone vs Immunoglobulins Alone With Course of Fever in Multisystem Inflammatory Syndrome in Children
Naïm Ouldali, MD, PhD1,2,3; Julie Toubiana, MD, PhD4,5; Denise Antona, MD6; Etienne Javouhey, MD, PhD7,8; Fouad Madhi, MD9; Mathie Lorrot, MD, PhD10; Pierre-Louis Léger, MD, PhD11; Caroline Galeotti, MD, PhD12; Caroline Claude, MD13; Arnaud Wiedemann, MD, PhD14,15; Noémie Lachaume, MD16; Caroline Ovaert, MD, PhD17,18; Morgane Dumortier, MD19; Jean-Emmanuel Kahn, MD, PhD20; Alexis Mandelcwajg, MD21; Lucas Percheron, MD22; Blandine Biot, MD23; Jeanne Bordet, MD24; Marie-Laure Girardin, MD25; David Dawei Yang, MD26; Marion Grimaud, MD27; Mehdi Oualha, MD, PhD27; Slimane Allali, MD, PhD4; Fanny Bajolle, MD28; Constance Beyler, MD29; Ulrich Meinzer, MD, PhD1,30; Michael Levy, MD, PhD31; Ana-Maria Paulet, MD32; Corinne Levy, MD2,33; Robert Cohen, MD2,33; Alexandre Belot, MD, PhD34; François Angoulvant, MD, PhD26,35; for the French Covid-19 Paediatric Inflammation Consortium
doi : 10.1001/jama.2021.0694
JAMA. 2021;325(9):855-864
Importance Multisystem inflammatory syndrome in children (MIS-C) is the most severe pediatric disease associated with severe acute respiratory syndrome coronavirus 2 infection, potentially life-threatening, but the optimal therapeutic strategy remains unknown.
Change in Reported Adherence to Nonpharmaceutical Interventions During the COVID-19 Pandemic, April-November 2020
Matthew A. Crane, BS1; Kenneth M. Shermock, PharmD, PhD2; Saad B. Omer, MBBS, MPH, PhD3; John A. Romley, PhD4
doi : 10.1001/jama.2021.0286
JAMA. 2021;325(9):883-885
Association Between COVID-19 Lockdown Measures and Emergency Department Visits for Violence-Related Injuries in Cardiff, Wales
Jonathan P. Shepherd, PhD1; Simon C. Moore, PhD1; Abigail Long, BA2; Laura M. Mercer Kollar, PhD3; Steven A. Sumner, MD4
doi : 10.1001/jama.2020.25511
JAMA. 2021;325(9):885-887
Regulation of Health Care Prices
Michael E. Chernew, PhD1; Maximilian J. Pany, BA1,2
doi : 10.1001/jama.2020.26821
JAMA. 2021;325(9):817-818
Paying for Prescription Drugs in the New Administration
Aaron S. Kesselheim, MD, JD, MPH1; Thomas J. Hwang, AB1; Jerry Avorn, MD1
doi : 10.1001/jama.2021.0009
JAMA. 2021;325(9):819-820
SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants
John P. Moore, PhD1; Paul A. Offit, MD2
doi : 10.1001/jama.2021.1114
JAMA. 2021;325(9):821-822
Data and Policy to Guide Opening Schools Safely to Limit the Spread of SARS-CoV-2 Infection
Margaret A. Honein, PhD1; Lisa C. Barrios, DrPH1; John T. Brooks, MD1
doi : 10.1001/jama.2021.0374
JAMA. 2021;325(9):823-824
Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic
James C. Robinson, PhD, MPH1
doi : 10.1001/jama.2020.25384
JAMA. 2021;325(9):825-826
Vaccine Distribution—Equity Left Behind?
Muriel Jean-Jacques, MD, MAPP1; Howard Bauchner, MD2
doi : 10.1001/jama.2021.1205
JAMA. 2021;325(9):829-830
Blinatumomab for Treatment of Children With High-risk Relapsed B-Cell Acute Lymphoblastic Leukemia
Neerav Shukla, MD1; Maria Luisa Sulis, MD1
doi : 10.1001/jama.2021.1395
JAMA. 2021;325(9):830-832
Diagnosis and Treatment of Irritable Bowel Syndrome
Michael Camilleri, MD1
doi : 10.1001/jama.2020.22532
JAMA. 2021;325(9):865-877
Importance The prevalence of irritable bowel syndrome (IBS) in the United States is between 7% and 16%, most common in women and young people, with annual direct costs estimated at more than $1 billion dollars in the United States. Traditionally, the diagnosis of IBS has been based on the positive identification of symptoms that correlate with several different syndromes associated with disorders such as IBS diarrhea, IBS constipation, functional diarrhea, functional constipation, chronic functional abdominal pain, or bloating. Several peripheral and central mechanisms initiate gastrointestinal motor and sensory dysfunctions leading to IBS symptoms. Those dysfunctions may require evaluation in patients whose symptoms do not respond to first-line treatments.
Diagnosis and Treatment of Nonscarring Hair Loss in Primary Care in 2021
Paradi Mirmirani, MD1,2,3; Jennifer Fu, MD1
doi : 10.1001/jama.2020.19313
JAMA. 2021;325(9):878-879
An EUA for Bamlanivimab—A Monoclonal Antibody for COVID-19
doi : 10.1001/jama.2020.24415
JAMA. 2021;325(9):880-881
Researchers Investigate What COVID-19 Does to the Heart
Jennifer Abbasi
doi : 10.1001/jama.2021.0107
JAMA. 2021;325(9):808-811
Experts Discuss COVID-19—Vaccine Doses, Virus Variants, and More
doi : 10.1001/jama.2021.1101
JAMA. 2021;325(9):812-813
Monthly Injection Is Approved for Patients With HIV
Rebecca Voelker, MSJ
doi : 10.1001/jama.2021.1932
JAMA. 2021;325(9):816
Rules Finalized for New Tobacco Product Approvals
Rebecca Voelker, MSJ
doi : 10.1001/jama.2021.1478
JAMA. 2021;325(9):816
Import Alert on Hand Sanitizers From South of the Border
Rebecca Voelker, MSJ
doi : 10.1001/jama.2021.1934
JAMA. 2021;325(9):816
Trade-offs in Public Health Insurance Design
Katherine Baicker, PhD1
doi : 10.1001/jama.2021.0647
JAMA. 2021;325(9):814-815
Reason for Everything
Lauren Elizabeth Claus, BA1
doi : 10.1001/jama.2020.23985
JAMA. 2021;325(9):892
“A General Practitioner,” or All for Mercy’s Sake
doi : 10.1001/jama.2020.17822
JAMA. 2021;325(9):893
Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines
Edward H. Livingston, MD1
doi : 10.1001/jama.2021.1375
JAMA. 2021;325(9):898
The De-adoption of Low-Value Health Care
Alberto Donzelli, MD1
doi : 10.1001/jama.2020.25515
JAMA. 2021;325(9):887-888
The De-adoption of Low-Value Health Care—Reply
Brian W. Powers, MD, MBA1; Sachin H. Jain, MD, MBA2; William H. Shrank, MD, MHSA1
doi : 10.1001/jama.2020.25518
JAMA. 2021;325(9):888
Antiretroviral Drug Recommendations for HIV Treatment and Prevention
Noga Shalev, MD1; Karen F. Brudney, MD1; Matthew L. Scherer, MD1
doi : 10.1001/jama.2020.25987
JAMA. 2021;325(9):888-889
Antiretroviral Drug Recommendations for HIV Treatment and Prevention—Reply
Michael S. Saag, MD1; Rajesh T. Gandhi, MD2; Paul E. Sax, MD2
doi : 10.1001/jama.2020.25990
JAMA. 2021;325(9):889-890
Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention
Hyun Kuk Kim, MD, PhD1; Jacek Kubica, MD2; Young-Hoon Jeong, MD, PhD3
doi : 10.1001/jama.2020.26020
JAMA. 2021;325(9):890
Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention—Reply
Seng Chan You, MD, MS1; Aakriti Gupta, MD, MS2; Harlan M. Krumholz, MD, SM3
doi : 10.1001/jama.2020.26023
JAMA. 2021;325(9):890-891
